Highlights
- Second quarter net loss was USD 14,558,426 against USD 8,827,510 a year earlier.
- Cash and cash equivalents were USD 42,990,371 at June 30, 2026.
- Management expects cash to last into the fourth quarter of 2027.
- Nasdaq sent a minimum bid price letter on July 29, 2026.
Context Therapeutics Inc. (NASDAQ:CNTX) shares were trading near their all-time low at USD 0.1918 on November 6, 2026, up 2.08% on the day. The clinical-stage company reported a second quarter net loss of USD 14,558,426, or USD 0.15 per share.
Context is advancing T-cell engager bispecific antibodies for solid tumors, including CTIM-76, a CLDN6 x CD3 engager, and CT-202, a Nectin-4 x CD3 engager.
Pipeline Prioritization
On August 5, 2026, the company announced a portfolio prioritization and Capital allocation strategy. It discontinued internal development of CT-95, a mesothelin x CD3 engager, and will focus on CTIM-76 and CT-202.
The filing describes CTIM-76 as intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6, a tight junction membrane protein that appears in multiple solid tumors and is absent from or low in healthy adult tissues. The FDA cleared the IND application for CTIM-76 on May 2, 2024.
Results
The loss from operations was USD 14,967,491 against USD 9,758,362. The net loss was USD 14,558,426 against USD 8,827,510, and the loss per share was USD 0.15 against USD 0.09. Research and Development expenses increased by approximately USD 4.7 million in the quarter.
For the six months, the loss from operations was USD 24,311,290 against USD 15,287,505. The net loss was USD 23,238,998, or USD 0.24 per share, against USD 13,404,771, or USD 0.14 per share.
Cash and Runway
Cash and cash equivalents were USD 42,990,371 at June 30, 2026 against USD 65,995,228 at December 31, 2025. The company expects its cash to be sufficient to fund operations into the fourth quarter of 2027.
Net cash used in Operating Activities was USD 18,449,111 for the six months against USD 10,863,561, and net cash used in investing activities was USD 4,555,746 against USD 33,948. The accumulated Deficit was USD 154.1 million.
Balance Sheet and Listing
Total Assets were USD 46,134,154 against USD 68,493,768. Total liabilities were USD 7,962,103 against USD 8,020,041, and total stockholders' Equity was USD 38,172,051 against USD 60,473,727.
On July 29, 2026, the company received a letter from Nasdaq stating that its closing bid price had been below USD 1.00 for 30 consecutive Business days and that it no longer complied with the minimum bid price requirement for the Nasdaq Capital Market. There were 91,879,177 shares outstanding as of August 3, 2026.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...